Hematuria Treatment Market is Segmented By Type (Drugs, Therapies), By Disease Type (Microscopic Hematuria, Gross Hematuria), By End-User (Hospitals, Specialty Clinics, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview
Hematuria Treatment Market is estimated to reach at a CAGR 2.8% during the forecast period (2024-2031).
The presence of blood in the urine can range from obvious to microscopic and undetectable. The presence of blood in a person's urine is known as hematuria. The most common cause of hematuria is urinary tract infections (UTIs).
As per DataM Intelligence, Hematuria Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Hematuria Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Hematuria Treatment Market in the United States and Canada produces the utmost share. Whereas the European Hematuria Treatment Market is projected to continue its presence globally during the period of 2024-2031.
Market Summary
| Metrics | Details |
| Market CAGR | 2.8% |
| Segments Covered | By Type, By Disease Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Market Dynamics
The factors influencing the global hematuria treatment market are the increasing demand for treatment and the growing prevalence of hematuria treatment.
The increasing demand for treatment of hematuria is expected to drive the market growth
The presence of blood or blood cells in the urine is known as hematuria. Although blood in the urine is not always a sign of disease, it can be a crucial indicator of a potential health problem. Urine that is bloody should never be ignored. The treatment for hematuria is highly dependent on the cause of blood in the urine. The best treatment option is determined using the information gathered from the medical history, physical exam, and any test results. The incidence of hematuria is increasing, and people over the age of 35 are more likely to develop the symptoms of hematuria. According to information circulated by the International Incontinence Society, 70 percent to 80 percent of people over the age of 80 experience symptoms of overactive bladder function. Moreover, blood in the urine can occur for a variety of reasons, such as hepatitis, a virus that causes liver disease and inflammation, viral illness, such as hepatitis a virus that causes liver disease and inflammation, sexual activity, endometriosis, or menstrual endometriosis, in which the tissue that normally lines the uterus grows elsewhere, such as the bladder. Hence, with increasing reasons for hematuria, the demand for its treatment is expected to grow.
Lack of awareness is expected to hamper the market growth
Microscopic hematuria is a common condition that affects 9 to 18 percent of people who appear to be healthy. Mariani et al. looked at 1000 patients with hematuria and found that 9.1% had life-threatening lesions, but the disease was localized in 92 percent of the cases. Urinary bleeding has been linked to anticoagulants like aspirin and blood thinners. Furthermore, some anti-cancer drugs have been linked to this ailment. Familial idiopathic hematuria is a type of idiopathic hematuria that runs in families. When there is no family history of kidney failure, and all other medical tests come back negative, there is usually no need for treatment. Hence, with limited information and knowledge, the global hematuria treatment market is expected to be hampered.
COVID-19 Impact Analysis
The sudden outbreak of the fatal coronavirus pandemic has been a major source of concern for the global hematuria treatment market's operations and treatments in the current forecast period. The arrival of the pandemic has caused major disruptions in the global market's demand and supply chain mechanisms, and medical professionals are solely focused on treating patients who have succumbed to the pandemic's fatalities, which are followed by rising cases and non-stop waves of the pandemic of various infection variants. The operation theatres and other medical rooms prioritize the treatment of covid positive patients, and a team of doctors and other medical personnel is devoting their time and resources to this cause. Moreover, blood urea nitrogen (BUN), creatinine, uric acid, D-dimer levels, proteinuria, and hematuria are signs of kidney failure. According to a study on hospitalization, 60 percent of 147 COVID-19 patients developed proteinuria, and 48 percent had hematuria. Hence, covid-19 is expected to positively and negatively impact the market.
Market Segment Analysis
Microscopic Hematuria segment is expected to dominate the market growth
Microhematuria, or microscopic blood traces in the urine, can occur for various reasons, including strenuous exercise or kidney stones. Microhematuria is frequently discovered during routine testing rather than as a result of symptoms. Although microhematuria isn't contagious, the most common cause is a urinary tract infection (which isn't contagious either). When it comes to cancer and microhematuria, the chances are higher as one gets older and smokes or uses tobacco products. The cause determines the treatment for microscopic hematuria. If testing reveals no cause for microscopic hematuria, treatment may not be required, and observation may be advised. Antibiotics may be prescribed if a patient has a urinary tract infection. The doctor may prescribe medication to shrink the prostate, relax the bladder, or both if the patient has an enlarged prostate. Surgical treatment may be necessary in some cases. When three to five red blood cells per high-power field are visible, microscopic hematuria, a common finding on routine urinalysis in adults, is clinically significant. Microscopic hematuria has many causes, from minor irritations to life-threatening urinary tract neoplasm.
Moreover, adults with asymptomatic microscopic hematuria have a prevalence of 0.19 to 21%. Asymptomatic microscopic hematuria is common in women, but it is less likely to be linked to women's urinary tract cancer than in men. The strongest predictors of urologic cancer in women are over 60 years old, smoking history, and gross hematuria.
Market Geographical Analysis
North America region is expected to hold the largest market share in the global hematuria treatment market
The factors such as favorable medical reimbursement policies, recent FDA approvals, a large number of drugs in the pipeline, and a growing focus on reducing the number of undiagnosed hematuria cases, the availability of early treatment is expected to drive the market in this region.
Microscopic hematuria is a condition that affects between 2% and 31% of people in the United States of America. Individuals over the age of 60 and those with a current or previous smoking history have higher rates. Urologic cancer is diagnosed in only a small percentage of people with microhematuria. About 2% to 3% of those with hematuria have a urologic malignancy when asymptomatic populations are screened with dipstick and/or microscopy medical testing. Screening regularly is not advised. Individuals with risk factors who have multiple tests have a higher risk of urologic cancer.
Market Competitive Landscape
With mergers, acquisitions, and product launches, the global hematuria treatment market is moderately competitive. Some of the key players in the market are Johnson & Johnson, Cipla Ltd., Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Pfizer Inc., Aurobindo Pharma USA, Zambon USA Ltd., GlaxoSmithKline plc.
Teva Pharmaceuticals Industries Ltd.
Overview: Teva Pharmaceutical Industries Ltd., headquartered in Petah Tikva, Israel, is an Israeli multinational pharmaceutical company. Its primary business is generic drugs, but it also deals in active pharmaceutical ingredients and proprietary pharmaceuticals to a lesser extent.
Product Portfolio: Antibiotics commonly treat hematuria caused by a urinary tract infection (UTI). These antibiotics kill the bacteria causing the UTI, halting the bleeding. For instance, the company's amoxicillin tablets are a penicillin-class antibiotic used to treat ear, nose, throat, and genitourinary tract infections caused by susceptible strains of microorganisms.
